Screening and Identifying m6A Regulators as an Independent Prognostic Biomarker in Pancreatic Cancer Based on The Cancer Genome Atlas Database

Abstract

Background. Pancreatic cancer is one of the most malignant tumors of the digestive system, and its treatment has rarely progressed for the last two decades. Studies on m6A regulators for the past few years have seemingly provided a novel approach for malignant tumor therapy. m6A-related factors may be potential biomarkers and therapeutic targets. This research is focused on the gene characteristics and clinical values of m6A regulators in predicting prognosis in pancreatic cancer. Methods. In our study, we obtained gene expression profiles with copy number variation (CNV) data and clinical characteristic data of 186 patients with pancreatic cancer from The Cancer Genome Atlas (TCGA) portal. Then, we determined the alteration of m6a regulators and their correlation with clinicopathological features using the log-rank tests, Cox regression model, and chi-square test. Additionally, we validated the prognostic value of m6A regulators in the International Cancer Genome Consortium (ICGC). Results. The results suggested that pancreatic cancer patients with ALKBH5 CNV were associated with worse overall survival and disease-free survival than those with diploid genes. Additionally, upregulation of the writer gene ALKBH5 had a positive correlation with the activation of AKT pathways in the TCGA database. Conclusion. Our study not only demonstrated genetic characteristic changes of m6A-related genes in pancreatic cancer and found a strong relationship between the changes of ALKBH5 and poor prognosis but also provided a novel therapeutic target for pancreatic cancer therapy.

Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer

“…To accurately detect the expression of m6A regulators in PAAD, we integrated seven independent datasets, with a total of 930 patients with PAAD. Although M6A-related regulators have been reported in pancreatic cancer (23,24). Geng et al reported m6A-related genes and m6A RNA methylation regulators in PAAD and their prognostic performance based on TCGA database (25).…”

Copy Number Variations in Pancreatic Cancer: From Biological Significance to Clinical Utility

“…The identification of these amplification and deletion events is therefore one of the main goals of medical genetics research. Indeed, CNVs have been observed in patients with pancreatic ductal adenocarcinoma (PDAC) [74][75][76][77][179][180][181][182][183][184][185][186][187]. However, the detection of CNVs and their subsequent association with functional and clinical phenotypes remains very challenging.…”

“…Indeed, CNVs have been observed in patients with pancreatic ductal adenocarcinoma (PDAC) [ 74 , 75 , 76 , 77 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 ]. However, the detection of CNVs and their subsequent association with functional and clinical phenotypes remains very challenging.…”